Aussie Company Care A2 Gains FDA Approval to Address US Infant Formula Shortages SYDNEY, July 09, 2022 (GLOBE NEWSWIRE) -- Care A2 , an Australian health and wellness company, today announced it has been approved by the United States Food Drug Administration (FDA) to deliver up to 4.8 million tins of Australian-made Care A2 Premium Infant Formula with Iron and added Lactoferrin to the U.S., to help offset the ongoing U.S. infant formula crisis. The FDA announced in Washington D.C. on 8 July 2022 that it had granted Care A2 ''no objection'' approval to distribute infant formula in the U.S., certifying that the Australian-made Care A2 formula meets the standards set by the FDA. Shipments are expected to commence progressively from the first week of August 2022. First orders have been received by the Company for over 250,000 tins of infant formula that will be available to be purchased across 20,000 retail locations nationwide, including CVS Rite Aid Drug Stores, Whole Foods Market, Kroger, HCA Healthcare, Publix Super Markets, Safeway, The Vitamin Shoppe, Duane …